TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05905601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NORTH
Description: NORTH is a native mobile app that provides on-demand content to young adults at risk for psychosis to improve or maintain their well-being, coping skills, and healthy habits, knowledge of psychosis, and provide help-seeking resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NORTH Lite
Description: NORTH Lite contains the same on-demand lessons, practices and tracking features found in the Full NORTH mobile application but does not include help-seeking resources.
Study: NCT06048913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 400mg plus normal saline 250ml intravenous infusion for not less than 60 minutes. Starting from week 1 of radiotherapy, 1 dose of the same dose each time for a total of 6 doses. The use of Taixinsen is not interrupted due to interruption of radiotherapy during the administration until the end of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigio
Description: Oral chemotherapy with the tigio regimen is given on days 1 to 2 of radiotherapy, with the drug dose calculated based on body surface area, and the oral tigio course from Monday to Friday is synchronized with radiation therapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent radiation therapy
Description: Outline the target area layer by layer on the enhanced CT image, PGTV, PTV. The endangered organs are delineated layer by layer on the cross-section, and extended 0.3cm to form a corresponding plan to endanger the organs. The reverse intensity modulated radiotherapy plan was designed on the Monaco treatment plan system, with a prescribing dose of 56Gy/30F for PTV and 60Gy/30F for pGTV, and the target dose distribution and organ exposure dose were evaluated layer by layer on a cross-sectional surface, and combined with dose-to-volume histogram (DVH) evaluation and optimal treatment plan, the maximum dose of radiation in the spinal cord \< 40 Gy and lung V20\<30%. After the treatment plan is confirmed, the dose is verified on the treatment machine, and the treatment plan is executed after it is accurate. govern
Study: NCT06566170

Intervention type: DRUG
Intervention: Usual Care
Description: Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.

Intervention type: DRUG
Intervention: Usual Care
Description: Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting.
Study: NCT05913713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Intervention Period
Description: Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Intervention Period
Description: Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12-week Intervention Period
Description: Research participants will be randomly assigned to either high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or the usual care (UC) group for a 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Observation Period
Description: After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week Observation Period
Description: After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12-week Observation Period
Description: After a 12-week intervention period (HIIT, MICT, or UC), research participants will have a 12-week observation period to assess the durability of two types of different exercises.
Study: NCT05089266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR T cells
Description: αPD1-MSLN-CAR T Cells
Study: NCT05961111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type 1 (R130)
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT06009991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Age 45-64: Remimazolam Besylate 0.3 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).~Age over 65: Remimazolam Besylate 0.15 mg/kg for anesthesia induction (0.05mg/kg for additional need) and 0.5mg/kg/h for maintenance (0.25 mg/kg/h for additional need).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Age 45-64: Propofol 3.0μg/ml TCI for anesthesia induction and 2.5-3.0μg/ml TCI for maintenance.~Age over 65: Propofol 1.5-2.5μg/ml TCI for anesthesia induction and 1.5-2.5μg/ml TCI for maintenance
Study: NCT05064358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered.
Study: NCT05445583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Tracking (PAT)
Description: All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
Study: NCT06137430

Intervention type: DRUG
Intervention: Sodium-glucose cotransporter 2 inhibitor
Description: Sodium glucose cotransporter 2 inhibitiors

Intervention type: DRUG
Intervention: Sodium-glucose cotransporter 2 inhibitor
Description: Sodium glucose cotransporter 2 inhibitiors
Study: NCT06078371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid-free pain treatment
Description: Pain treatment includes any medications up to the medical team's discretion aside from opioids.
Study: NCT06411327

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented reality
Description: Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented reality
Description: Augmented Reality Devices - data collected from the Guiding-Pad app will be fed to two AR devices (i.e. team leader and medication nurse), which will provide role-specific decision support for these two providers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LCD Screen
Description: LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LCD Screen
Description: LCD Screen - data collected from the Guiding-Pad app will be fed to the LCD screen, which will be mounted on a wall, in clear view for the entire resuscitation team to see.
Study: NCT05927519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq video laryngoscope
Description: airtraq video laryngoscope will be used for intubations

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: airtraq video laryngoscope
Description: airtraq video laryngoscope will be used for intubations
Study: NCT05107011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-015 for Injections
Description: Initial dose - MTD ; Q2W ; intravenous infusion
Study: NCT06215859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-107A-02
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: over-encapsulated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: over-encapsulated tablet and/or tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: over-encapsulated tablet and/or tablet
Study: NCT04801849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Participants will be assigned to take 200 IU, 400 IU, or 800 IU of vitamin E in matching capsules daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a placebo vitamin E capsule daily for 24 weeks
Study: NCT05130320

Intervention type: OTHER
Intervention: Not Interventional their treatments are their routine NHS care
Description: Not Interventional their treatments are their routine NHS care

Intervention type: OTHER
Intervention: Not Interventional their treatments are their routine NHS care
Description: Not Interventional their treatments are their routine NHS care
Study: NCT05267470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion
Study: NCT05130320

Intervention type: OTHER
Intervention: Not Interventional their treatments are their routine NHS care
Description: Not Interventional their treatments are their routine NHS care
Study: NCT05222620

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: Undergo single fraction SRS

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Radiosurgery
Description: Undergo fractionated SRS

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06651151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 + pembrolizumab
Description: LTX-315 as intratumoral injection once weekly for a maximum of 5 dosing days, in combination with pembrolizumab as intravenous infusion, 200 mg every 3 weeks for a maximum of 18 doses
Study: NCT04793204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant
Description: oral
Study: NCT05083611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GraMI
Description: The intervention will last 6 weeks. Each technique lasts for 2 weeks. The first two techniques will be performed through the previously designed mobile application and the last technique will be performed through a mirror box. The patient can do it autonomously with the supervision of the principal investigator.
Study: NCT05709223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Categorical loudness scaling based fitting using the Nexus Research System.
Description: The Nexus Research system is used in combination with other devices as part of a hearing implant system. It is intended to create and modify hearing profiles, to monitor the performance of the system and to facilitate Firmware updates of the system. It is also intended to be used with other devices of a hearing implant system to make volume adjustments to the processing unit, to download pre-defined MAPs and to collect data from tests and questionnaires using a compatible device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Behavioural fitting using Custom Sound Suite (CSS 6.3) Software
Description: The comparator is the commercially available fitting method (i.e., the behavioural measurement of active channels) using Custom Sound Suite (CSS 6.3) software
Study: NCT04616313

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized Xenon-129 MRI of the lungs
Description: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized Xenon-129 MRI of the lungs
Description: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized Xenon-129 MRI of the lungs
Description: Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography (CT)
Description: Participants will undergo a CT scan of the thoracic cavity

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography (CT)
Description: Participants will undergo a CT scan of the thoracic cavity

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography (CT)
Description: Participants will undergo a CT scan of the thoracic cavity

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests (PFT)
Description: Participants will have their lung function evaluated using PFT

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests (PFT)
Description: Participants will have their lung function evaluated using PFT

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function Tests (PFT)
Description: Participants will have their lung function evaluated using PFT
Study: NCT06135350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
Description: Treatment arm patients will receive Fluorothiazinone, tablets 300 mg at a dose:~* 2400 mg/day (4 tablets twice a day) for the first 2 days and;~* 1800 mg/day (3 tablets twice a day) from the third day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm patients will receive placebo:~* 4 tablets twice a day for the first 2 days and;~* 3 tablets twice a day and further (but no more than 14 days) until the occurrence of ventilator-associated pneumonia caused by gram-negative bacteria, confirmed clinically and microbiologically, OR the completion of the patient's participation in the study for other reasons.~Tablets are taken 2 times a day 12 hours apart 30 minutes after meal, no more than 14 days.
Study: NCT04747418

Intervention type: PROCEDURE
Intervention: Diagnostic Hysteroscopy
Description: Collection of first 5 cc of normal saline from the output port during diagnostic hysteroscopy
Study: NCT05592145

Intervention type: DEVICE
Group type: OTHER
Intervention: ViOptix
Description: ViOptix machine
Study: NCT05715840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001 injection
Description: 360 mg，Q3W，IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2，Q3W，IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2，Q3W，IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 50 mg/m\^2，Q3W，IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m\^2，Q3W，IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: AUC=5，Q3W，IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=5，Q3W，IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab injection
Description: 15 mg/kg，Q3W，IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab injection
Description: 15 mg/kg，Q3W，IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SG001 placebo
Description: Q3W，IV infusion
Study: NCT04616313

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: Participants will perform cardiopulmonary exercise testing as a measure of exercise capacity

Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum analysis
Description: Participants will provide a sputum sample that will be analysed for eosinophils

Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum analysis
Description: Participants will provide a sputum sample that will be analysed for eosinophils

Intervention type: DIAGNOSTIC_TEST
Intervention: Sputum analysis
Description: Participants will provide a sputum sample that will be analysed for eosinophils

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Participants will have their blood drawn and analysed for eosinophil count.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Participants will have their blood drawn and analysed for eosinophil count.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood analysis
Description: Participants will have their blood drawn and analysed for eosinophil count.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will complete questionnaires to assess activity related dyspnea, respiratory symptoms and health status impairment and respiratory related quality of life.